Artis BioSolutions, an advanced therapies company in San Diego, established new synthetic DNA manufacturing capabilities in Boston utilizing Bilbao, Spain-based Syngoi Technologies’ proprietary enzymatic platform. This expansion strategically extends Artis’ regional capabilities, integrating with their advanced therapy development and GMP manufacturing facility in Watertown, MA, to deliver efficient solutions for its global customer base, according to Brian Neel, CEO of Artis.
“Artis was founded to more effectively provide platforms and capabilities that drug developers require to bring next-generation medicines to patients,” continued Neel. “Establishing U.S.-based synthetic DNA manufacturing is a pivotal step in the evolution of the Artis platform and reinforces our mission to integrate specialized technologies—from synthetic DNA through GMP manufacturing—into a seamless, end-to-end offering.
By offering Syngoi Technologies at our U.S. site, we are delivering a much-needed capability to our customers focused on early development through clinical manufacturing while strengthening our global operational resilience.”
By operating production hubs…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
